BioAge Labs (BIOA) Gross Margin (2025 - 2026)
BioAge Labs (BIOA) posted Gross Margin of 374.06% for Q1 2026, up 25.9% sequentially from 504.84% in Q4 2025, and down 15504.0% YoY from N/an in Q1 2025.
BioAge Labs (BIOA) Gross Margin (2025 - 2026) Analysis & Trends
BioAge Labs has reported Gross Margin for 2 years, with the latest figure at 374.06% in Q1 2026.
- Quarterly Gross Margin fell 15504.0% year-over-year to 374.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 461.86% (up 199845.0% YoY) and the FY2025 annual result came in at 449.74%, changed N/A from the prior year.
- Gross Margin grew to 374.06% in Q1 2026 per BIOA's latest filing, from 504.84% in the prior quarter.
- Over five years, Gross Margin peaked at 219.02% in Q1 2025 and troughed at 504.84% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | BioAge Labs | 437.85 Mn | 437.85 Mn | -14.23 Mn | -580.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -580.46% |
| Mar 31, 2026 | -374.06% |
| Dec 31, 2025 | -504.84% |
| Sep 30, 2025 | -496.30% |
| Jun 30, 2025 | -478.57% |
| Mar 31, 2025 | -219.02% |